120 related articles for article (PubMed ID: 18761330)
21. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
22. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
Wandl S; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():242-9. PubMed ID: 19723061
[TBL] [Abstract][Full Text] [Related]
23. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Zulehner N; Maurer M; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
[TBL] [Abstract][Full Text] [Related]
24. Prevention of p53 degradation in human MCF-7 cells by proteasome inhibitors does not mimic the action of roscovitine.
Ranftler C; Gueorguieva M; Wesierska-Gadek J
Ann N Y Acad Sci; 2006 Dec; 1090():234-44. PubMed ID: 17384267
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.
Kramer MP; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():257-63. PubMed ID: 19723063
[TBL] [Abstract][Full Text] [Related]
26. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells.
Mohapatra S; Chu B; Zhao X; Pledger WJ
Cancer Res; 2005 Sep; 65(17):7717-23. PubMed ID: 16140939
[TBL] [Abstract][Full Text] [Related]
27. Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
Wesierska-Gadek J; Gueorguieva M; Herbacek I; Ranftler C
Ann N Y Acad Sci; 2007 Jan; 1095():45-52. PubMed ID: 17404016
[TBL] [Abstract][Full Text] [Related]
28. Common and reversible regulation of wild-type p53 function and of ribosomal biogenesis by protein kinases in human cells.
David-Pfeuty T; Nouvian-Dooghe Y; Sirri V; Roussel P; Hernandez-Verdun D
Oncogene; 2001 Sep; 20(42):5951-63. PubMed ID: 11593402
[TBL] [Abstract][Full Text] [Related]
29. Interplay between the p53 tumor suppressor protein family and Cdk5: novel therapeutic approaches for the treatment of neurodegenerative diseases using selective Cdk inhibitors.
Schmid G; Strosznajder JB; Wesierska-Gadek J
Mol Neurobiol; 2006 Aug; 34(1):27-50. PubMed ID: 17003520
[TBL] [Abstract][Full Text] [Related]
30. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
[TBL] [Abstract][Full Text] [Related]
32. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
34. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
35. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
[TBL] [Abstract][Full Text] [Related]
36. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
37. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.
Węsierska-Gądek J; Kramer MP
Expert Opin Investig Drugs; 2011 Dec; 20(12):1611-28. PubMed ID: 22017180
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.
Gritsch D; Maurer M; Zulehner N; Wesierska-Gadek J
J Exp Ther Oncol; 2011; 9(1):37-45. PubMed ID: 21275264
[TBL] [Abstract][Full Text] [Related]
39. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Wesierska-Gadek J; Kramer MP; Maurer M
Food Chem Toxicol; 2008 Apr; 46(4):1327-33. PubMed ID: 17933449
[TBL] [Abstract][Full Text] [Related]
40. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]